Investment
Features
FeesSafety
Academy
More
Pluang+

Flexible Solutions International upgraded to Speculative Buy as food-grade contracts boost growth prospects

Analyst Insights
18 Aug 2026
Seeking Alpha
View Source
Bullish
Flexible Solutions International upgraded to Speculative Buy as food-grade contracts boost growth prospects

Flexible Solutions International, Inc. (FSI) has been upgraded to Speculative Buy due to strong progress in its food-grade chemical production and the ramp-up of major contracts. While the company faces short-term profitability challenges from scaling up food production, management expects profitability to return in Q3 and earnings to accelerate in Q4. Key food contracts guarantee at least $6.5 million in annual revenue, with a target of over $50 million combined and projected gross margins of 22–25%. Although current stock valuation seems high, successful execution and increased volumes could significantly improve profitability and valuation by 2027.

More News

Stellantis unveils six bold concept cars ahead of the Paris Motor Show, showcasing future mobility and design innovation.

Stellantis unveils six bold concept cars ahead of the Paris Motor Show, showcasing future mobility and design innovation.

Stellantis revealed six concept cars from its iconic brands at an exclusive event before the Paris Motor Show, highlighting its FaSTLAne 2030 strategy focused on innovation, customer experience, and diverse mobility solutions. These concepts, includi...

Market News
Bullish
1 hour ago
New version of Freenome's blood test shows improved detection of advanced precancerous colorectal lesions

New version of Freenome's blood test shows improved detection of advanced precancerous colorectal lesions

Freenome announced improved clinical validation results for its updated SimpleScreen™ CRC blood test, showing an 18.2% sensitivity for advanced precancerous lesions (APLs), up from 13.7% in the original test. Sensitivity for high-grade dysplasia APLs...

Market News
Bullish
1 hour ago
Encaleret boosts bone turnover and improves symptoms in ADH1 patients, with FDA Priority Review underway.

Encaleret boosts bone turnover and improves symptoms in ADH1 patients, with FDA Priority Review underway.

BridgeBio Pharma announced that encaleret, a treatment for autosomal dominant hypocalcemia type 1 (ADH1), increased bone turnover and improved patient-reported symptoms in the Phase 3 CALIBRATE trial. 100% of patients on encaleret reported symptom im...

Company Fundamentals
Bullish
3 hours ago
Strategy plans to keep buying Bitcoin after $176M STRC stock buyback, signaling ongoing BTC accumulation.

Strategy plans to keep buying Bitcoin after $176M STRC stock buyback, signaling ongoing BTC accumulation.

Strategy announced it repurchased $176 million of its STRC preferred stock while acquiring 334 BTC in Q3 2026, reporting a $21 billion gain on digital assets. Michael Saylor confirmed that Bitcoin purchases will continue, framing the STRC buyback as ...

Market News
Bullish
4 hours ago
Ethereum gas fees hit a 7-day low, making transactions cheaper but signaling weak network demand.

Ethereum gas fees hit a 7-day low, making transactions cheaper but signaling weak network demand.

Ethereum's gas fees have dropped to an average base fee of 0.0673 gwei over the past 24 hours, about one-sixth of the weekly average, reflecting half-empty blocks and reduced network activity. This low fee means transaction costs are minimal, benefit...

Protocol Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App